Making a new category

"Mibefradil is, pharmacologically, an exciting new molecule that has opened up many new avenues for research. Its selective T-channel-blocker activity led to its classification as a new category of calcium antagonist. This classification perhaps led to the perception that somehow it was above the problems associated with older calcium antagonists."
-Li Wan Po, Zhang (1998)

Li Wan Po A, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 20 June 1998: 351: 9119: 1829-30